FDA Approves Wegovy Pill: A New Era in Weight Loss
FDA Approves Wegovy Pill: A New Era in Weight Loss
The FDA greenlights the first oral Wegovy, a GLP-1 weight-loss pill, with daily dosing rules and a $149 starting price.
The US FDA has approved an oral Wegovy pill, marking the first time a GLP-1 weight-loss drug is available in pill form. The medicine uses semaglutide, the same active ingredient as the injectable Wegovy and Ozempic, but it is taken daily on an empty stomach with a small amount of water. After dosing, patients are advised not to eat, drink, or take other medicines for 30 minutes.
Novo Nordisk plans to launch the Wegovy pill in early January in the United States. The drug will come in a 1.5 mg dose, with the initial lowest dose priced at about $149 for out-of-pocket purchases. Dosing typically starts low and increases over several weeks to manage side effects.
Wegovy’s oral form joins a family that includes injectable Wegovy and Lilly’s Zepbound, both GLP-1 drugs used for obesity. Semaglutide works by suppressing appetite, helping many patients lose weight; the pill version continues that approach but in a daily pill rather than weekly injections. Novo Nordisk also makes a pill version of semaglutide for diabetes, called Rybelsus, highlighting the drug family’s expansion beyond injections.
Experts and patients alike are watching how this new option will affect access to treatment, insurers, and real-world adherence. While the injection options have already transformed obesity care, a pill could expand reach, though costs and out-of-pocket expenses could still pose barriers.
This approval signals a broader shift in obesity treatment, but as with any medication, results will vary and long-term safety data will continue to emerge. The Wegovy pill represents a step into a new era for weight-loss medications.
